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Abstract
Amplification of MYCN is the most well-known prognostic marker of neuroblastoma risk classification, but still is only observed in 25% of
cases. Recent evidence points to the cyclic adenosine monophosphate (cAMP) elevating ligand prostaglandin E2 (PGE2) and b-catenin as two
novel players in neuroblastoma. Here, we aimed to define the potential role of PGE2 and cAMP and its potential interplay with b-catenin, both of
which may converge on neuroblastoma cell behaviour. Gain and loss of b-catenin function, PGE2, the adenylyl cyclase activator forskolin and
pharmacological inhibition of cyclooxygenase-2 (COX-2) were studied in two human neuroblastoma cell lines without MYCN amplification. Our
findings show that PGE2 enhanced cell viability through the EP4 receptor and cAMP elevation, whereas COX-2 inhibitors attenuated cell viability.
Interestingly, PGE2 and forskolin promoted glycogen synthase kinase 3b inhibition, b-catenin phosphorylation at the protein kinase A target res-
idue ser675, b-catenin nuclear translocation and TCF-dependent gene transcription. Ectopic expression of a degradation-resistant b-catenin
mutant enhances neuroblastoma cell viability and inhibition of b-catenin with XAV939 prevented PGE2-induced cell viability. Finally, we show
increased b-catenin expression in human high-risk neuroblastoma tissue without MYCN amplification. Our data indicate that PGE2 enhances
neuroblastoma cell viability, a process which may involve cAMP-mediated b-catenin stabilization, and suggest that this pathway is of relevance
to high-risk neuroblastoma without MYCN amplification.
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Introduction
Neuroblastomas are heterogeneous tumours that vary to a large
extent in prognosis and disease outcome and are responsible for
15% of all childhood cancer deaths [1]. Although recent studies have
focused on the link between proliferation, differentiation and pro-
grammed cell death in neuroblastoma, understanding of the molecu-
lar mechanisms driving neuroblastoma heterogeneity is poor. The
most extensively defined factor associated with neuroblastoma is the
Myc oncoprotein family member MYCN, which is especially amplified
in the most aggressive and often metastatic forms of neuroblastoma
[2, 3]. Although MYCN has important prognostic value, amplification
is only observed in about 25% of neuroblastoma cases and it remains
largely to be defined what other factors contribute to high-risk neuro-
blastoma.
Expression of cyclooxygenase-2 (COX-2) and prostaglandin E2
(PGE2) have been found increased in a variety of malignant tumours,
including neuroblastoma [4, 5] and pharmacological inhibition of
COX-2 has been shown to attenuate cell cycle progression in
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malignant cells [6–9]. PGE2 is produced by a multistep enzymatic
process in which the rate-limiting step is mediated by COX enzymes.
PGE2 binds to its membrane bound E-type prostanoid receptors, of
which prostanoid receptors type 2 and 4 are known to couple to Gas
and are thereby able to increase intracellular cyclic adenosine mono-
phosphate (cAMP) levels. cAMP is involved in the regulation of
diverse cellular processes, including regulation of cytoskeletal
dynamics, cellular differentiation, proliferation and programmed cell
death in a variety of cells including neural-like cells [10, 11].
Of particular interest are recent research lines that focus on
molecular interactions between PGE2, cAMP and b-catenin. b-catenin
contributes to other malignancies such as hepatocellular carcinoma
and colorectal carcinoma and its role in paediatric malignancies is
well documented [12]. Also, its role in normal physiological develop-
ment of pluripotent cells from the neural crest has been well-estab-
lished [13–15]. Regarding neuroblastoma, b-catenin expression is
increased in MYCN non-amplified neuroblastoma cell lines and
b-catenin target gene transcription is increased in neuroblastoma
tumours without MYCN amplification [16].
Distinct pools of b-catenin exhibit distinct cellular functions.
b-Catenin associates with membrane junctional complexes where it
binds to cadherins and a-actin. Free cytosolic b-catenin is rapidly
tagged for proteasomal degradation by a multiprotein destruction
complex comprised of the kinases glycogen synthase kinase 3b
(GSK3b), casein kinase 1 and adaptor proteins like axin2, which
is the limiting component in the assembly of this complex
[17–19]. Stabilized b-catenin translocates to the nucleus, where it
activates transcription of TCF/Lef target genes. The result is
expression of mitogenic and survival genes including Myc onco-
gene family members [20] and cyclin D1 [21]. Interestingly, PGE2
has been shown to enhance b-catenin nuclear localization via
dissociation of GSK3b from axin by Gas [22] and by activating
protein kinase A (PKA) [23]. Activated PKA can directly phosphor-
ylate b-catenin at residue ser675 [24] and GSK3b at residue ser9
[10, 25, 26].
In this paper, we aim to identify the contribution of a molecular
link between PGE2 and b-catenin to cell proliferation and inhibition of
apoptosis, independent of MYCN amplification.
Materials and methods
Cell culture
Human neuroblastoma cell lines SK-N-AS and SK-N-SH were obtained
from ATCC (Manassas, VA, USA). Both cell lines are of epithelial mor-
phology. Cells were maintained in DMEM (1.0 g/l glucose, HEPES)
supplemented with 10% v/v heat-inactivated FCS, non-essential amino
acids and antibiotics (penicillin 100 U/ml, streptomycin 100 l/ml) in a
humidified atmosphere of 5% CO2 at 37°C. Cells were washed with
HBSS (400 mg/l KCl, 60 mg/l KH2PO4, 8 g/l NaCl, 350 mg/l NaHCO3,
50 mg/l Na2HPO4H2O, 1 g/l glucose, pH 7.4), dissociated from the
plate with trypsin EDTA and seeded in appropriate cell culture plate
format. Cells were serum-deprived for 24 hrs before stimulation.
Inhibitors (XAV939, celecoxib and niflumic acid) or antagonists
(AH6809 and L-161,982) were added 30 min. prior to stimulation with
PGE2.
Cell viability assay
Experiments were performed in 24-well cell culture plates. Prior to mea-
surement, cells were washed with calcium containing HBSS (400 mg/l
KCl, 60 mg/l KH2PO4, 8 g/l NaCl, 140 mg/l CaCl2, 100 mg/l MgCl26H2O,
100 mg/l MgSO47H2O, 90 mg/l Na2HPO47H2O, 1 g/l glucose, pH 7.4)
and then incubated with 5% v/v AlamarBlue (Invitrogen, Carlsbad, CA,
USA) followed by fluorescence spectrophotometry. Treated cultures were
normalized to control cultures.
cAMP assay
Experiments were performed in 24-well cell culture plates. When indi-
cated, cells were pre-incubated with niflumic acid for 2 hrs. Cells were
incubated in serum-free DMEM supplemented with 0.1 mM 3-Isobutyl-
1-methylxanthine for 10 min at 37°C with indicated stimuli. A radioac-
tive competitive binding assay was used to determine cAMP levels, as
described earlier [27, 28, 29, 30].
Colony formation assay
Cells were seeded in six-well plates. Cells were incubated in DMEM for
14 days with indicated stimuli. Medium was refreshed every 3 days.
Cells were fixed with paraformaldehyde (PFA) and stained with 0.05%
Crystal Violet. Plates were photographed and confluency was quantified
using ImageJ software.
PGE2 ELISA
Cells were cultured in 24-well plates and PGE2 production was mea-
sured in culture medium from overnight cultures incubated with niflu-
mic acid using the PGE2 ELISA assay from Cisbio (Codolet, France).
Fluorescence-activated cell sorting
Cells were cultured on 60 mm plates and incubated for 24 hrs with
designated stimuli. For cell cycle analysis, cells were incubated for
30 min. with 30 lM bromodeoxyuridine (BrdU). Cells were dissociated
from the plate with accutase, fixed with 95% EtOH and DNA was dena-
tured using 2M HCl. Cells were incubated with anti-BrdU FITC-conju-
gated antibody, propidium iodide (PI) and RNAse A. A total of 40,000
stained cells in FACS buffer (PBS containing 1% v/v BSA, 20 mM
EDTA) were analysed in FACSCalibur (BD Biosciences, Franklin Lakes,
NJ, USA). ModFit LT software was used to determine the distribution of
cells over the cell cycle phases designated G0/G1, S and G2/M. For
detection of apoptosis, cells were washed with binding buffer (140 mM
NaCl, 4 mM KCl, 0.75 mM MgCl2, 10 mM HEPES). A total of 400,000
cells were resuspended in ice-cold binding buffer supplemented for
15 min. with 2 mM CaCl2, PI (1 lg/ml) and FITC-conjugated annexin V
antibody (IQ Products, Groningen, The Netherlands). A total of 10,000
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stained cells were analysed by Kaluza Flow Analysis Software (Beckman
Coulter, Brea, CA, USA).
JC-1 mitochondrial membrane polarization assay
Cells were seeded in 24-well plates and incubated with designated stim-
uli for 24 hrs and mitochondrial membrane polarization was measured
using the Mitochondrial Staining Kit (Sigma-Aldrich, Munich, Germany).
Isolation of mRNA and real-time PCR analysis
Total mRNA extraction was performed with the NucleoSpin RNA II Kit
(Machery-Nagel, D€uren, Germany). cDNA was acquired using reverse
transcription by AMV Reverse Transcriptase Kit (Promega, Madison,
WI, USA). qPCR was performed with the Illumina Eco Personal qPCR
System (Westburg, Leusden, The Netherlands). Cycle parameters
(30 sec. each): denaturation at 94°C, annealing at 60°C and extension
at 72°C. Target genes were normalized to the geometric mean of refer-
ence genes GAPDH, SDHA and YWHAZ [29]. Primer sequences are
listed in Table 1.
Transfection
Cells grown to 60% confluence were transfected in serum- and antibiot-
ics-free DMEM with plasmid DNA [TOPflash, FOPflash, renilla luciferase
(Upstate Biotechnology, Charlottesville, VA, USA), b-cateninS33Y (Add-
Gene plasmid 19286, Cambridge, MA, USA) [30], pcDNA3 vector] using
X-tremeGENE 9 DNA transfection reagent (Roche Applied Science,
Penzberg, Germany).
TOP flash assay
TOPflash- or FOPflash-transfected cells were subjected to stimulation in
serum-free DMEM for 16 hrs, and luciferase activity was assayed via
the Dual Reporter luciferase assay system (Promega).
Preparation of nuclear fractions
Cell were seeded in 100 mm cell culture dishes and dissociated with a
cell scraper. Cells were incubated with hypotonic buffer (25 mM HEPES
pH 7.5, 10 mM KCl, 1 mM EDTA, 0.2 mM Na3VO4, 50 mM NaF, b-glyc-
erophosphate, 10% v/v glycerol, pepstatin A, leupeptin, apoprotinin) for
10 min. on ice and 15 min. with 0.1% v/v IGEPAL added. After centrifu-
gation at 3000 9 g for 3 min., the supernatant (cytosolic fraction) was
collected and pellets were resuspended in ice-cold cell extraction buffer
(25 mM HEPES pH 7.5, 420 mM NaCl, 10% w/v sucrose, 10 mM KCl,
1 mM EDTA, 10% v/v glycerol, 50 mM NaF, 0.2 mM Na3VO4, b-glyc-
erophosphate, pepstatin A, leupeptin, apoprotinin) for 30 min. After cen-
trifugation at 14,000 9 g for 10 min., supernatant (nuclear fraction)
was collected.
Immunoblotting
Cells were lysed in ice-cold RIPA buffer supplemented with phospha-
tase and protease inhibitors (aprotinin, leupeptin, pepstatin A,
Na3VO4, NaF, b-glycerophosphate). Equal amounts of protein were
subjected to electrophoresis on polyacrylamide gels and transferred
to nitrocellulose membranes. Membranes were blocked with 5% w/v
BSA or 5% w/v milk in tris-buffered saline with 0.1% v/v Tween-20.
Protein expression was determined by specific primary and horserad-
ish peroxidase (HRP)-conjugated secondary IgGs. Antibodies used are
listed in Table 2. Protein expression was visualized by ECL in the
Syngene G:BOX HR iChemi gel documentation system (Syngene,
Cambridge, UK). Band was quantified by densitometry using ImageJ
software.
Immunofluorescence
Cells were grown on LabTek II Chamber Slides (Thermo Fisher Scientific,
Marietta, OH, USA), fixed with PFA and permeabilized with 0.3% w/v Tri-
ton X-100 in cytoskeletal buffer (10 mM Tris, 150 mM NaCl, 5 mM EGTA,
5 mM MgCl2, 5 mM glucose, pH 6.1). Cells were blocked using 1% w/v
BSA and 2% v/v donkey serum in CytoTBS-T (20 mM Tris, 154 mM NaCl,
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2 mM EGTA, 2 mM MgCl2, 0.1% v/v Tween-20, pH 7.2). p-b-Catenin
(ser675) IgG was applied overnight, secondary FITC-conjugated donkey
anti-rabbit IgG (Jackson Laboratories, Bar Harbor, ME, USA) was applied
for 3 hrs. Nucleus was visualized with 1 lg/ml Hoechst 33342 (Invitro-
gen). Slides were mounted with ProLong Gold Antifade Reagent (Life
Technologies, Marietta, OH, USA). Images were captured with a Leica
DM4000 B Fluorescence microscope (Leica Microsystems, Wetzlar,
Germany) equipped with a Leica DFC 345 FX camera.
Study population and samples
Formalin-fixed paraffin-embedded tumour samples from 31 neuroblasto-
mas were analysed. All samples were collected at our own hospital
between 1984 and 2012 according to the Research Code of the Univer-
sity Medical Center Groningen (https://www.umcg.nl/en/research/
researchers/general/researchcode/pages/default.aspx) and national ethi-
cal and professional guidelines (Code of Conduct; Dutch Federation of
Biomedical Scientific Societies; http://www.federa.org). Tumour speci-
mens were subdivided based on risk group assessment in low risk,
medium risk and high risk according to Children’s Oncology Group risk
groups (Table 3).
Fluorescence in situ hybridization
Fluorescence in situ hybridization was performed to exclude MYCN-
amplified tumours from the study population. Tissue sections were
hybridized with Vysis LSI N-MYC (2p24) SpectrumGreen/CEP2 Spec-
trumOrange Probe (Abbott Molecular, Green Oaks, IL, USA). The LSI
N-MYC (2p24) probe hybridizes to the 2p24 region and contains
sequences that flank both 50 and 30 ends of the MYCN gene. The CEP2
(2p11.1-q11.1) probe hybridizes to alpha satellite sequences specific to
chromosome 2. Images were captured using a Leica DMRA2 Fluores-
cence microscope (Leica Microsystems) equipped with a Leica DC350F
camera. The number of spots in 20 adjacent tumour cells was counted
Table 2 Primary antibodies
Antibody Source (catalogue number) Dilution
Cyclin D1 Cell Signaling (2926) 1:1000
Histone H3 Cell Signaling (9715) 1:500
PARP Cell Signaling (9542) 1:1000
p-GSK3a/b (ser21/9) Cell Signaling (9331) 1:500
p-b-Catenin (ser675) Cell Signaling (4176) 1:2000
a-Tubulin Millipore (05-829) 1:2000
Active b-Catenin Millipore (05-665) 1:1000
b-Catenin (total) BD Biosciences (610153) 1:2000
Table 3 The Children’s Oncology Group (COG) risk group classification
Risk group Stage (INSS) Age Histology DNA Ploidy MYCN
Low risk Stage 1 Any Any Any Any
Stage 2A/B <12 months Any Any Any
Stage 2A/B >12 months Any Any Non-Amplified
Stage 4S <12 months Favourable Hyperdiploid Non-Amplified
Medium risk Stage 3 <12 months Any Any Non-Amplified
Stage 3 >12 months Favourable Any Non-Amplified
Stage 4 <12 months Any Any Non-Amplified





High risk Stage 2A/B >12 months Any Any Amplified
Stage 3 Any Any Any Amplified
Stage 3 >18 months Unfavourable Any Any
Stage 4 Any Any Any Amplified
Stage 4 >18 months Any Any Any







Stage 4S <12 months Any Any Amplified
ª 2014 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
213
J. Cell. Mol. Med. Vol 19, No 1, 2015
for MYCN and CEP2. When ratio between the two signals exceeded 2,
the tumour was scored as MYCN amplified.
Immunohistochemistry
For determination of b-catenin protein expression, deparaffinized tumour
sections were incubated with anti-b-catenin IgG (1:25 in 1% v/v goat
serum, 1% v/v human serum) overnight and subsequent with HRP-
conjugated rabbit antimouse IgG (1:1000; DAKO, Glostrup, Denmark).
Staining was performed with 0.5 mg/ml 3,30-diaminobenzidine in
30 mM imidazole containing 0.03% v/v H2O2 and 1 mM EDTA, pH 7.0.
As a negative control, the primary antibodies were omitted. For each
sample, expression was quantified by measuring the average staining
intensity on a scale of 256 channels using ImageJ software in four dif-
ferent random selected regions within the tumour (using haematoxylin
and eosin-stained sections). Differences between the groups were
tested for significance using the Kruskal–Wallis test. All procedures
were performed blind.
Reagents
BrdU, mouse anti-BrdU antibody, PI, L-161,982 and celecoxib were pur-
chased from Sigma-Aldrich. 16,16-dimethyl-PGE2, XAV939, AH6809 and
forskolin were from Tocris Bioscience (Bristol, UK). Niflumic acid was
from Cayman Chemical (Ann Arbor, MI, USA). All other chemicals were
of analytical grade.
Statistics
Data represent means  SEM, from n separate experiments. Normality
and equal variance were evaluated by Shapiro–Wilk test and f-test. Sta-
tistical significance of differences was evaluated by Student’s t-test and
one-way or two-way ANOVA followed by a Tukey multiple comparison
test. Non-parametric data were evaluated with the Kruskal–Wallis test
followed by Dunn’s multiple comparison test. Differences were consid-
ered to be statistically significant when P < 0.05.
Results
cAMP and PGE2 enhance neuroblastoma cell
viability
To study the effects of cAMP elevation on MYCN non-amplified neu-
roblastoma cell viability, SK-N-AS cells were incubated for the indi-
cated periods of time with the direct adenylyl cyclase activator
forskolin or PGE2 (Fig. 1A). Forskolin or PGE2 enhanced time-depen-
dently cellular viability compared to control treated cells. To deter-
mine that PGE2 could act via elevation of cAMP, we measured
intracellular cAMP levels. Cells show increase in cAMP levels after
incubation with forskolin compared to basal. Similar, 16,16-dimethyl-
PGE2 (in this paper referred to as PGE2) induces cAMP elevation
(Fig. 1B).
In addition, expression of cyclin D1, a cell cycle regulatory protein
involved in G1/S-phase transition, is increased by both forskolin and
PGE2 (Fig. 1C).
Prostaglandin E2 mediates its effects through activation of four
subtypes of E-type prostanoid receptors, termed EP1-4. Of these
receptors, EP2 and EP4 are known to be Gas-coupled and enhance
intracellular cAMP. SK-N-AS neuroblastoma cells express all four
receptor subtypes (Fig. 1D). To study which receptor is involved in
enhancement of cell viability by PGE2, the EP2 and EP4 receptor were
antagonized using AH6809 and L-161,982 respectively. AH6809 did
not affect PGE2-enhanced cell viability. However, L-161,982 com-
pletely prevented enhancement of cell viability by PGE2 (Fig. 1E),




Prostaglandin E2 is produced by a multistep enzymatic process from
arachidonic acid, in which the rate-limiting step is mediated by COX.
Expression of COX-2 is increased in many cancers, including neuro-
blastoma, resulting in high PGE2 production [31]. As PGE2 enhances
cell cycle progression, inhibition of PGE2 production by COX-2 inhibi-
tion should attenuate cell proliferation. In overnight culture, neuro-
blastoma cells produce PGE2 (150 pg/ml) and COX-2 inhibition with
niflumic acid decreases PGE2 (6 pg/ml). Importantly, niflumic acid
decreases dose-dependently viability of SK-N-AS cells (Fig. 2A). To
confirm that the niflumic acid data were the result of COX-2 inhibition,
another COX-2 inhibitor was used, celecoxib. Similar to niflumic acid,
celecoxib treatment resulted in a marked decrease in cell viability
(Fig. 2B). To visualize decreased cell survival over a longer time, cells
were cultured for 14 days in a colony formation assay in the presence
or absence of either niflumic acid (Fig. 2C) or celecoxib (Fig. 2D).
Confluency was markedly decreased in the presence of specific COX-
2 inhibitors which was more pronounced when higher concentrations
of COX-2 inhibitor were used.
Cyclooxygenase-2 inhibition blocks cell cycle
progression and activates an apoptotic response
To clarify mechanisms underlying the reduction in cell survival by
COX-2 inhibition, we studied cell cycle progression and apoptotic
pathway activation. Cell cycle progression was first studied by BrdU
incorporation followed by fluorescence-activated cell sorting using
cytometry (Fig. 3A). PI was used to measure the overall DNA content
of cells. Niflumic acid reduced the amount of BrdU-positive cells and
cells with a ploidy between 2n (cells in G0/G1) and 4n (cells in G2/M),
indicating a lower fraction of cells in S-phase. In contrast, induction
of apoptosis was studied by sorting cells based on membrane expres-
sion of annexin V (Fig. 3B). Viable cells are located in the lower left
quadrant (double negative), early apoptotic cells are located in
the lower right quadrant (annexin V positive, PI negative) and late
apoptotic cells are located in the upper right quadrant (double
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positive). Niflumic acid treatment exerts a higher percentage of cells
in late apoptosis, while the percentage of cells in early apoptosis was
not affected. To confirm apoptotic pathway activation, we measured
aggregation of the JC-1 dye at mitochondrial membranes. A distinc-
tive feature of the early stages apoptosis is the disruption of active
mitochondria, which includes changes in the membrane potential. In
healthy, polarized membranes, the JC-1 dye spontaneously forms
aggregates with red fluorescence (EM 590 nm), while in apoptotic
cells, the JC-1 dye remains in its monomeric form (EM 529 nm). Inhi-
bition of COX-2 with niflumic acid results in attenuated mitochondrial
membrane polarization (Fig. 3C). Valinomycin served as a positive
control.
Amplification and thereby increased expression of N-Myc is the
best known marker for neuroblastoma risk profile [1–3]. N-Myc is
a positive regulator of cell cycle progression and a negative regula-
tor of programmed cell death. COX-2 inhibition with niflumic acid
decreased expression of N-Myc mRNA (Fig. 3D). To further distin-
guish between inhibition of cell cycle progression and induction of
apoptotic signalling, we looked for expression of cyclin D1. Niflu-
mic acid attenuated expression of cyclin D1, which is consistent
with the cell cycle analysis shown in Figure 3A. Finally, niflumic
acid-induced cleavage of the apoptosis linked Poly ADP ribose
polymerase (PARP) (Fig. 3E).
Rescue of cyclooxygenase-2-dependent cell
survival by exogenous prostaglandin E2
To confirm that the decreased viability of neuroblastoma cells in





Fig. 1 Effect of PGE2 and forskolin on SK-N-AS cell viability. (A) Cell viability after 24- and 48-hr incubation with 10 lM forskolin or 3 lM PGE2. (B)
cAMP formation under basal (1.8  0.38 pmol/min/mg/protein), forskolin (23.04  0.31/pmol/min/mg protein) and PGE2 (4.79  0.64 pmol/min/
mg protein)-treated conditions. (C) Representative Western blot images showing expression of cyclin D1 after 8-hr incubation with forskolin or
PGE2. (D) qRT-PCR detection of EP1-4 mRNA expression (Cq values) and representative bands on agarose gel. (E) Cell viability after 48-hr incuba-
tion with 10 lM AH6809 and 3 lM L-161,982 in combination with PGE2. Data represent mean  SE of the mean of four separate experiments.
*P < 0.05, **P < 0.01, ***P < 0.001 compared to DMSO-treated cells.
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levels, cells were incubated with niflumic acid absence or presence of
exogenous PGE2. We used a concentration of niflumic acid that
results in 75% viability compared to control-treated cells. Reduced
viability resulting from COX-2 inhibition by niflumic acid was
completely restored by exogenous PGE2 in a dose-dependent manner
(Fig. 4A). In addition, niflumic acid treatment resulted in a marked
decrease in cAMP production, which was rescued by simultaneous
addition of exogenous PGE2 (Fig. 4B).
Likewise, exogenous PGE2 prevented inhibition of colony forma-
tion induced by COX-2 inhibition (Fig. 4C). Similarly, celecoxib atten-
uated neuroblastoma cell viability, which was restored by exogenous
PGE2 (Fig. 4D).
cAMP enhances b-catenin stability and activates
b-catenin target gene transcription
b-catenin stability and transcriptional activity are known to determine
the balance between cell proliferation and differentiation and are
involved in the progression of several cancers [32]. Because several
recent reports suggest that PGE2 can enhance b-catenin stability and
transcriptional activity [22, 33–36], we aimed to identify the effects of
forskolin and PGE2 on b-catenin stability and transcriptional activity.
In response to cAMP elevation, PKA is activated. PKA can phosphory-
late b-catenin and GSK3b (see introduction). b-catenin not phosphor-
ylated by GSK3b is stable and translocates to the nucleus. In this
A B
C D
Fig. 2 Effect of specific COX-2 inhibition on SK-N-AS cell viability. (A) Cell viability after 48-hr incubation with indicated concentrations of niflumic
acid (IC50 SK-N-AS 355 lM). (B) Cell viability after 48-hr incubation with 50 lM celecoxib. (C and D) Representative pictures of a colony formation
assay. Data represent mean  SE of the mean of 4–10 separate experiments. **P < 0.01, ***P < 0.001 compared to DMSO-treated cells.
Fig. 3 COX-2 inhibition decreases cell cycle progression and induces apoptotic events in SK-N-AS cells. (A) Cell cycle analysis after 200 lM niflumic
acid. (B) Niflumic acid-induced apoptosis was analysed by annexin V labelling. Lower left: viable cells; lower right: early apoptotic cells; upper right:
late apoptotic/necrotic cells. (C) Mitochondrial membrane polarization was measured with JC-1 in cells incubated with niflumic acid. (D) qPCR data
showing N-Myc mRNA expression after 16-hr incubation with niflumic acid. (E) Representative Western blot images showing niflumic acid-induced
PARP cleavage and expression of Cyclin D1 after 24 hrs. Data represent mean  SE of the mean of 4–10 separate experiments. ***P < 0.001
compared to DMSO-treated cells.
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paper, we refer to this stable form of b-catenin as active b-catenin.
Neuroblastoma cells stimulated with forskolin or PGE2 were analysed
for protein levels of phosphorylated b-catenin and GSK3b. Forskolin
and PGE2 induced phosphorylation of b-catenin (ser675), p-GSK3b
(ser9) and concomitant higher levels of active, unphosphorylated,
b-catenin (Fig. 5A). It has been reported that phosphorylation of
b-catenin by PKA (ser675) enhances b-catenin stability and its
nuclear translocation [24, 37, 38]. b-Catenin localization was deter-
mined by analysis of cytosolic (C) and nuclear fractions (N)
(Fig. 5B). Phosphorylation of b-catenin (ser675) was increased in
both nuclear and cytosolic fractions by cAMP and PGE2. Levels of
active b-catenin were increased in nuclear fractions by cAMP and
A B
C D
Fig. 4 Attenuated cell viability of SK-N-AS cells in response to COX-2 inhibition can be restored by PGE2. (A) Viability after 48-hr incubation with
niflumic acid in the absence or presence of the indicated concentrations of PGE2. (B) cAMP formation in response to niflumic acid with and without
PGE2. (C) Representative pictures of a colony formation assay. (D) Cell viability after 48-hr incubation with 25 lM celecoxib and PGE2. Data repre-
sent mean  SE of the mean of four separate experiments. *P < 0.05, **P < 0.01 compared to DMSO-treated cells, #P < 0.05, ##P < 0.01 com-
pared to COX-2 inhibitor-treated cells.
Fig. 5 b-Catenin activity is enhanced by PGE2 and forskolin in SK-N-AS cells. (A) Representative Western blot images of active b-catenin, p-b-cate-
nin (ser675) and p-GSK3b (ser9) in cells incubated with forskolin or PGE2 for 30 min. (B) Representative Western blot images of cytosolic (C) and
nuclear fractions (N) of active b-catenin and p-b-catenin (ser675) in cells incubated with forskolin or PGE2 for 30 min. (C) Representative immuno-
fluorescence images of p-b-catenin (ser675) in response to forskolin or PGE2 for the indicated periods of time. White arrows indicate presence at
(peri)nuclear regions. (D) TOPFlash assay of cells incubated with forskolin or PGE2. Data represent mean  SE of the mean of four separate experi-
ments. *P < 0.05, ***P < 0.001 compared to DMSO-treated cells.
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PGE2. To visualize localization of p-b-catenin (ser675), neuroblas-
toma cells were stimulated with forskolin or PGE2 after which
p-b-catenin (ser675) was visualized by immunofluorescence
(Fig. 5C). Both forskolin and PGE2 transiently increased levels of
p-b-catenin (ser675) and induced accumulation of p-b-catenin
(ser675) in (peri)nuclear regions (white arrows, Fig. 5C), which was
followed by a rapid decline. To assess b-catenin/TCF target gene
transcription in response to forskolin or PGE2, neuroblastoma cells
were transfected with a TCF luciferase reporter gene construct (TOP-
flash) containing multiple TCF-binding sites or a construct with
mutated TCF-binding sites (FOPflash). Either forskolin or PGE2
induced TCF reporter gene expression, as measured by luciferase
activity in cell lysates (Fig. 5D).
b-Catenin is involved in neuroblastoma cell
survival
To study if the effects of forskolin and PGE2 on cell survival are medi-
ated via b-catenin-dependent gene transcription in a non-Wnt ligand-
dependent manner, neuroblastoma cells were transfected with the
stable active mutant of b-catenin (b-cateninS33Y). Transfection with
b-cateninS33Y increased protein levels of b-catenin (Fig. 6A). Func-
tionally, b-cateninS33Y increased TCF reporter gene activity (Fig. 6B).
In addition, active b-catenin could enhance cellular viability and cell
cycle progression. Overexpression of b-cateninS33Y enhanced cell via-
bility compared to cells expressing the empty vector (Fig. 6D).
Conversely, we addressed whether b-catenin is required for PGE2-
induced neuroblastoma cell viability. To study this, we lowered active
(non-phosphorylated) b-catenin by enhancing the stability of axin2,
the limiting factor of the APC/GSK3b/CK1 destruction complex that
targets b-catenin for proteasomal degradation, with the tankyrase
inhibitor XAV939 [39]. Levels of active b-catenin were reduced by
XAV939 treatment, while total levels of b-catenin remained
unchanged (Fig. 6C). Importantly, while XAV939 prevented PGE2-
induced cell viability, it did not affect neuroblastoma cell viability at a
basal level (Fig. 6E). Thus, our data indicate that the effects of PGE2
on neuroblastoma involve active b-catenin.
SK-N-SH human neuroblastoma cells
Cancer cell lines are often characterized by cell line-specific
(genetic) abrogations that do not accurately reflect the behaviour of
other cancer cell lines originating from the same disease. We there-
fore repeated key experiments in a different human neuroblastoma
cell line without MYCN amplification, SK-N-SH. Similar to SK-N-AS,
forskolin and PGE2 enhanced SK-N-SH neuroblastoma cell viability,
while antagonism of the EP4 receptor with L-161,982 prevented
PGE2-enhanced cell viability which was not affected by antagonism
of the EP2 receptor using AH6809 (Fig. 7A and data not shown). In
addition, overexpression of b-cateninS33Y enhanced cell viability
(Figs 6D and 7B). Specific COX-2 inhibition with niflumic acid or
celecoxib (data not shown) attenuated cell viability in a dose-depen-
dent manner (Figs 2A and 7C). SK-N-SH cells were more sensitive
towards COX-2 inhibition compared to SK-N-AS. The PGE2-induced
enhanced cell viability was prevented by attenuating active b-catenin
with the tankyrase inhibitor XAV939 (Figs 6E and 7D). Thus,
SK-N-SH and SK-N-AS human neuroblastoma cell lines behave
similarly in response to manipulation of PGE2 or b-catenin signalling
properties.
High-risk neuroblastoma without amplification of
MYCN exhibit high b-catenin expression
Finally, we examined a potential correlation between b-catenin
expression in neuroblastoma tumour sections with neuroblastoma
risk profile. We investigated tumour specimens that were collected
and stored for diagnosis for expression of b-catenin protein by
immunohistochemistry. Characteristics of the investigated risk
group populations are listed in Table 4. We were only interested in
cases without MYCN amplification as it has previously been
reported that b-catenin expression is increased in neuroblastoma
tumours and cell lines without amplification of MYCN [16]. Fluores-
cence in situ hybridization was performed to identify amplification
status of neuroblastoma specimens. We regarded tumour speci-
mens that scored positive for MYCN amplification as a separate
group of tumours. b-Catenin expression was determined by scoring
the average staining intensity of the tumour. b-Catenin was found
predominantly at the periphery of the cell body and within the neu-
ropil, areas of the tumour that are comprised of non-myelinated ax-
ons, dendrites and synaptic dense regions. We did not observe b-
catenin-positive nuclei. When high-risk tumours with MYCN amplifi-
cation were compared to high-risk tumours without MYCN amplifi-
cation, higher levels of b-catenin were found in high-risk tumours
without MYCN amplification. Importantly, we observed higher levels
of b-catenin in tumour specimens from high-risk tumours com-
pared to expression in low- and medium-risk cases (P = 0.042)
(Fig. 8C).
Discussion
The development of neural crest-derived tissues is under tight con-
trol of molecular mechanisms that regulate proliferation, differentia-
tion and programmed cell death. When these core molecular
pathways become deregulated, malignancies such as neuroblas-
toma can develop. The most extensively defined factor contributing
to neuroblastoma pathogenesis is amplification of the Myc onco-
protein family member MYCN. Amplification of MYCN is only
observed in about one-fourth of neuroblastomas [1, 3]. In this
study, we focused on the contribution of PGE2 and b-catenin to
progression of neuroblastomas without MYCN amplification. Our
findings in MYCN non-amplified neuroblastoma cell lines show that
PGE2 enhances cell viability through the EP4 receptor, whereas this
was attenuated by inhibition of PGE2 with specific COX-2 inhibitors.
Elevating cAMP using forskolin mimicked the effects of PGE2 on
cell viability. PGE2 and cAMP promoted GSK3b inhibition,
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phosphorylation of b-catenin at the PKA target residue ser675,
b-catenin nuclear translocation and TCF-dependent gene transcrip-
tion. Furthermore, we show that expression of a degradation-resis-
tant b-catenin mutant enhances neuroblastoma cell viability and
that inhibition of b-catenin with XAV939 prevents PGE2-induced via-
bility. b-Catenin expression in tumour sections was increased in
high-risk neuroblastoma without MYCN amplification compared to
expression in low- or medium-risk sections. These data suggest
that autocrine PGE2 enhances neuroblastoma cell viability via a
mechanism involving cAMP-mediated b-catenin stabilization, and
suggest that this pathway is of relevance to high-risk neuroblas-





Fig. 6 Overexpression of a degradation-resistant mutant of b-catenin (b-cateninS33Y) in SK-N-AS cells and inhibition of b-catenin by XAV939. (A)
Representative Western blot images of b-cateninS33Y expression. (B) TOPFlash assay of cells expressing of b-cateninS33Y. (C) Representative Wes-
tern blot images of b-catenin expression in cells after 1 lM XAV939 treatment for 24 hrs. (D) Cell viability of cells expressing of b-cateninS33Y. (E)
Cell viability of cells incubated with PGE2 absence or presence of XAV939. Data represent mean  SE of the mean of four separate experiments.
*P < 0.05, ***P < 0.001 compared to DMSO-treated cells, #P < 0.05 compared to PGE2-treated cells.
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Increased PGE2 levels and concomitant up-regulation of COX-2
are frequently observed in malignant tissues of epithelial origin [5,
40]. Studies have revealed that inhibition of COX enzymes have
potential in anticancer therapy [40]. Regarding neuroblastoma,
studies indicate that COX-2 and PGE2 are involved in progression
of neuroblastoma [4, 5], although it is largely unknown which
downstream molecular pathways are involved. PGE2 functions by
binding to its membrane bound E-type prostanoid receptors which
are all expressed in neuroblastoma cells. Of the four receptor sub-
types, EP2 and EP4 are Gas-coupled and stimulate adenylyl
cyclase activation and thus intracellular cAMP levels [41]. Indeed,
we found that PGE2 incubation elevated cellular cAMP levels in
neuroblastoma. Conversely, inhibiting endogenous PGE2 synthesis
with COX-2 inhibitors decreased cAMP levels. The rise in cAMP
levels, either through receptor-mediated adenylyl cyclase activation
by PGE2 or via direct activation of adenylyl cyclase by forskolin,
increased cell viability of neuroblastoma cells. Further, we demon-
strate that enhancement of cell viability by PGE2 is mediated
through the EP4 receptor as antagonism of the EP4 receptor using
L-161,982 completely abolished the enhancement of cell viability
by PGE2, whereas antagonism of the EP2 receptor using AH6809
did not affect this. In earlier studies, Rasmuson et al. demon-
strated that exogenous PGE2 enhanced viability of MYCN-amplified
SK-N-BE(2) neuroblastoma cells, suggesting that PGE2 is involved




Fig. 7 Viability of SK-N-SH human neuroblastoma cells after modulation by PGE2 and b-catenin. (A) Cell viability after 48 hrs of cells incubated with
forskolin or PGE2 and L-161,982. (B) Cell viability of cells expressing of b-catenin
S33Y. (C) Cell viability after 48-hr incubation with indicated concen-
trations of niflumic acid. (D) Cell viability of cells incubated with PGE2 in the absence or presence of XAV939. Data represent mean  SE of the
mean of 4–10 separate experiments. *P < 0.05, **P < 0.01, ***P < 0.001 compared to DMSO-treated cells, #P < 0.05 compared to PGE2-treated
cells.
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Inhibition of COX enzymes has been shown to inhibit neuroblas-
toma cell survival in vitro [7, 42] and to inhibit tumour growth in vivo
[5]. Indeed, COX-2 inhibitors attenuated cell viability in neuroblastoma
cells. In other studies, inhibition of COX-2 by celecoxib or diclofenac
changed mitochondrial membrane potential and subsequent activa-
tion of caspase-9- and caspase-3-dependent apoptosis [7, 43], while
no activation of caspase-8 or BID cleavage were observed, suggesting
involvement of the intrinsic apoptotic pathway. In this study, we
observed altered mitochondrial membrane potential after treatment
with COX-2 inhibitors. In addition, we found that COX-2 inhibition
induces apoptosis in neuroblastoma cells. Furthermore, we observed
attenuated cell cycle progression after COX-2 inhibition resulting from
a cell cycle block between G1 and S-phase. This cell cycle block was
further confirmed by decreased expression of cell cycle regulatory
A B
Fig. 8 b-Catenin expression is increased in high-risk neuroblastoma tumours without amplification of MYCN. (A) Characteristics of study population.
For this study, we focused on tumours that have no MYCN amplification. (B) Representative IHC pictures of low and high b-catenin expression. (C)
Quantification of average b-catenin intensity in tumours without amplification of MYCN. Boxes represent Q1, median (Q2) and Q3. Whiskers represent
minimum and maximum. *P < 0.05 (Kruskal–Wallis).
Table 4 Characteristics of study population
Risk (COG) n Sex Age (in months)
Stage (INSS)
Me St Pr Re De
1 2a/b 3 4 4S
Low 7/22 M5/F2 Median: 2
Range: 0–68
2/7 4/7 0/7 0/7 1/7 1/7 2/7 0/7 5/7 1/7
Medium 9/22 M7/F2 Median: 7
Range: 0–12
0/9 0/9 8/9 1/9 0/9 1/9 1/9 0/9 8/9 1/9
High 6/22 M3/F3 Median: 112
Range: 13–267
0/6 0/6 1/6 5/6 0/6 5/6 2/6 2/6 2/6 3/6
COG, Children’s Oncology Group; INSS, International Neuroblastoma Staging System; M: male; F: female; Me: metastatic; St: stable; Pr:
progressing; Re: remission; De: deceased.
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protein cyclin D1. Although it seems evident that the effects of COX-2
inhibition are mediated by decreased PGE2 production, there are
several reports that indicate that accumulation of arachidonic acid,
the precursor for PGE2 synthesis, is also involved. For instance,
combined treatment with arachidonic acid and COX inhibitors results
in a synergistic effect on cell survival [44]. However in this study, we
show that COX-2 inhibition with niflumic acid or celecoxib comple-
mented with exogenous PGE2, rescues neuroblastoma cells from
decreased viability as a result of COX-2 inhibition. This is also
reflected on intracellular cAMP levels, which are decreased by niflu-
mic acid, but restored by simultaneous addition of exogenous PGE2.
Of particular interest are emerging research lines that focus on
molecular interactions between PGE2 and b-catenin. In 2002, Fuji-
no et al. showed that PGE2 stimulates TCF/Lef promoter activity
through EP2 and EP4 receptor signalling [33]. Downstream of EP2
and EP4, an increase in cAMP levels activates PKA. Phosphoryla-
tion of GSK3b at ser9 by PKA inhibits its kinase activity and
thereby enhances b-catenin stability, nuclear translocation and
TCF/Lef-dependent gene transcription [23, 32, 33]. It was, how-
ever, unknown if this molecular interaction occurs in neuroblas-
toma. Stimulation of neuroblastoma cells with forskolin or PGE2
increased p-GSK3b (ser9) and elevated levels of unphosphorylated
b-catenin at the GSK3b residues. In addition, we found increased
nuclear localization of active b-catenin. These findings are in
agreement with studies in different malignant cell models. In non-
small cell lung cancer and colorectal cancer, PGE2 enhances
b-catenin nuclear localization and inhibits GSK3b by phosphorylation
which is dependent on cAMP and kinase activity of PKA [34, 36].
Apart from inhibiting GSK3b, PKA has been shown to directly acti-
vate b-catenin by phosphorylation at residue ser675 [24, 37, 38].
Indeed, we observed increased p-b-catenin (ser675) in response
to PGE2 or forskolin. Subsequently, we observed a transient
increase in p-b-catenin (ser675) at the (peri)nuclear regions.
Importantly, we also found increased TCF-dependent gene tran-
scription, which confirms earlier studies in HEK cells in which
PKA-dependent p-b-catenin (ser675) resulted in increased TCF
luciferase activity [24, 37]. More recently, increased TCF-depen-
dent gene transcription downstream of PGE2 and subsequent PKA
activity was found in in vitro and in vivo models for colorectal
cancer [23, 34]. Conversely, inhibition of PGE2 synthesis using the
COX-2 inhibitor celecoxib has been found to attenuate b-catenin
stability, nuclear translocation and TCF luciferase activity in colo-
rectal cancer [34, 35], non-small cell lung cancer [36], and osteo-
sarcoma [45], with concomitant lower expression of cyclin D1 and
cell survival.
The contribution of b-catenin and TCF-dependent gene tran-
scription in colorectal carcinoma has been well-established. In
neuroblastoma, it has been shown that b-catenin expression is
increased in MYCN non-amplified neuroblastoma cell lines [16].
The result of b-catenin transcriptional activity is expression of
mitogenic and survival genes. In this study, we demonstrate
increased TCF-dependent gene transcription and enhanced cellular
viability in neuroblastoma cells transfected with a b-catenin
mutant that is untargetable for proteasomal degradation (b-cate-
ninS33Y). Importantly, the enhanced cell viability resulting from
PGE2 was completely prevented by the tankyrase inhibitor
XAV939. XAV939 prevents tankyrase-mediated degradation of
axin2, thereby stabilizing axin2 which is the concentration-limiting
component of the destruction complex that sequesters b-catenin
and GSK3b. Thereby, XAV939 functions as an inhibitor of b-catenin
activity [39]. Thus, b-catenin is, at least to some extent, responsi-
ble for PGE2-induced enhanced cellular viability. Recently, XAV939
has been shown to decrease neuroblastoma cell survival by inhib-
iting b-catenin transcriptional activity and decreasing expression
of cyclin D1 in both MYCN-amplified and non-amplified cell lines
[46]. Moreover, knockdown of b-catenin using RNA interference
has been shown to inhibit cell cycle progression and induce apop-
tosis in neuroblastoma cells [47]. This, together with our data
indicates that b-catenin plays a crucial role in neuroblastoma cell
survival.
Interestingly, investigation of b-catenin expression in neuro-
blastoma tumour sections without MYCN amplification revealed
particularly high expression in high-risk tumours. This further
strengthens our hypothesis that b-catenin plays an important role
in neuroblastoma, not only in vitro cell models but also in a clini-
cally more relevant context. Other recent studies have also found
increased expression of b-catenin in neuroblastoma, which was
involved in maintaining a neuroblast-like phenotype of neuroblas-
toma cells and conferring resistance to chemotherapeutic agents
[48, 49]. However, these studies did not distinguish between
MYCN-amplified and non-amplified tumours. We are aware that
based on our study, we cannot draw strong conclusions on the
functional role of increased b-catenin in high-risk neuroblastoma
tumours as expression of b-catenin was found predominantly at
the cell periphery and the neuropil, where it exerts a different
function than in the nucleus. However, during epithelial–mesenchy-
mal transition, which is an early step in the metastatic cascade in
cancer [50], b-catenin is liberated from the junctional complexes
where it is sequestered. In such an event in the presence of a
b-catenin stabilizing stimulus such as PGE2, b-catenin translo-
cates to the nucleus and activates TCF/Lef-dependent transcrip-
tional programmes, thereby enhancing survival and metastatic
potential [51].
The promising therapeutic potential of COX-2 inhibitors has
resulted in multiple compounds that have reached the clinical market.
These compounds were, however, rejected as a consequence of con-
cerns regarding drug safety [40]. Recent insight in the systemic
effects of COX-2 inhibition and its metabolites, questions the notion
that the safety issues are the result of COX-2 inhibition and not COX-1
[52, 53]. We believe that with better insights in the molecular events
that occur downstream of COX inhibition, more specific chemopre-
ventive compounds might be developed that exploit the therapeutic
potential of specific COX-2 inhibition, but circumvent the safety
issues.
Taken together, our results demonstrate that PGE2 is an important
factor being involved in the regulation of neuroblastoma cell viability.
cAMP activates PKA and thereby stabilizes b-catenin either directly or
indirectly by inhibiting GSK3b, resulting in increased b-catenin activ-
ity and neuroblastoma cell viability. The increased expression of
b-catenin in high-risk neuroblastoma, without MYCN amplification,
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suggests that b-catenin could play a major role in neuroblastoma.
Thus, strategies that target either PGE2 production by the tumour
(COX-2 inhibitors) or target the interaction between PGE2 and b-catenin
warrant further investigation.
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